

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

ARISTADA

Products Affected:

- Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular
- Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular
- Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular

Details

Criteria
Claim will pay automatically for ARISTADA if enrollee has a paid claim for at least a 1 days supply of ABILIFY MAINTENA and LATUDA in the past 365 days. Otherwise, ARISTADA requires a step therapy exception request indicating: (1) history of inadequate treatment response with ABILIFY MAINTENA and LATUDA, OR (2) history of adverse event with ABILIFY MAINTENA and LATUDA, OR (3) ABILIFY MAINTENA and LATUDA are contraindicated.

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

AUBAGIO

Products Affected:

- Aubagio TABLET 14 MG ORAL
- Aubagio TABLET 7 MG ORAL

Details

Criteria	CLAIM WILL PAY AUTOMATICALLY FOR Aubagio IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF Gilenya or Tecfidera IN THE PAST 365 DAYS. OTHERWISE, Aubagio REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH Gilenya or Tecfidera, OR (2) HISTORY OF ADVERSE EVENT WITH Gilenya or Tecfidera, OR (3) Gilenya or Tecfidera IS CONTRAINDICATED.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

BPH

Products Affected:

- Rapaflo CAPSULE 4 MG ORAL
- Rapaflo CAPSULE 8 MG ORAL

Details

Criteria
CLAIM WILL PAY AUTOMATICALLY FOR RAPAFLO IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF ALFUZOSIN, DUTASTERIDE, DUTASTERIDE/TAMSULOSIN, FINASTERIDE OR TAMSULOSIN IN THE PAST 365 DAYS. OTHERWISE RAPAFLO REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH ALFUZOSIN, DUTASTERIDE, DUTASTERIDE/TAMSULOSIN, FINASTERIDE OR TAMSULOSIN, OR (2) HISTORY OF ADVERSE EVENT WITH ALFUZOSIN, DUTASTERIDE, DUTASTERIDE/TAMSULOSIN, FINASTERIDE OR TAMSULOSIN, OR (3) ALFUZOSIN, DUTASTERIDE, DUTASTERIDE/TAMSULOSIN, FINASTERIDE OR TAMSULOSIN IS CONTRAINDICATED.

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

BYSTOLIC

Products Affected:

- Bystolic TABLET 10 MG ORAL
- Bystolic TABLET 2.5 MG ORAL
- Bystolic TABLET 20 MG ORAL
- Bystolic TABLET 5 MG ORAL

Details

Criteria	Claim will pay automatically for Bystolic if enrollee has a paid claim for at least a 1 days supply of any 1 generic formulary beta-blocker in the past 365 days. Otherwise, Bystolic requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 1 generic formulary beta-blocker, OR (2) history of adverse event with any 1 generic formulary beta-blocker, OR (3) any 1 generic formulary beta-blocker are contraindicated.
-----------------	---

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

DIFICID

Products Affected:

- Dificid TABLET 200 MG ORAL

Details

Criteria	Claim will pay automatically for Dificid if enrollee has a paid claim for at least a 1 days supply of vancomycin in the past 120 days. Otherwise, Dificid requires a step therapy exception request indicating: (1) history of inadequate treatment response with Vancomycin, OR (2) history of adverse event with Vancomycin, OR (3) Vancomycin is contraindicated.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

LONG ACTING FENTANYL

Products Affected:

- FentaNYL Patch 72 Hour 100 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 25 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 37.5 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 50 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 62.5 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 75 MCG/HR Transdermal
- FentaNYL Patch 72 Hour 87.5 MCG/HR Transdermal

Details

Criteria
Claim will pay automatically for Fentanyl patches if enrollee has paid claims history for both Group A and Group B drugs. GROUP A Drugs: Any 1 days supply in the past 365 days of brand Opana ER or generic Oxymorphone ER (2) GROUP B Drugs: Any 1 days supply in the past 365 days of either Morphine ER or Methadone. Otherwise, the drug requires a step therapy exception request indicating any ONE of the following: (1) history of inadequate treatment response with Group A or Group B drugs, OR (2) history of adverse event with Group A or Group B drugs, OR (3) Group A or Group B drugs are contraindicated.

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

OVERACTIVE BLADDER

Products Affected:

- Myrbetriq Tablet Extended Release 24 Hour 25 MG Oral
- Myrbetriq Tablet Extended Release 24 Hour 50 MG Oral
- VESicare TABLET 10 MG ORAL
- VESicare TABLET 5 MG ORAL

Details

Criteria
Claim will pay automatically for Myrbetriq or Vesicare if enrollee has a paid claim for at least a 1 days supply of any formulary urinary anticholinergic in the past 365 days. Otherwise, Myrbetriq or Vesicare requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary urinary anticholinergic, OR (2) history of adverse event with formulary urinary anticholinergic, OR (3) formulary urinary anticholinergic is contraindicated.

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

PRADAXA

Products Affected:

- Pradaxa CAPSULE 110 MG ORAL
- Pradaxa CAPSULE 150 MG ORAL

Details

Criteria	CLAIM WILL PAY AUTOMATICALLY FOR Pradaxa IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF Xarelto or Eliquis IN THE PAST 365 DAYS. OTHERWISE, Pradaxa REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH Xarelto or Eliquis, OR (2) HISTORY OF ADVERSE EVENT WITH Xarelto or Eliquis, OR (3) Xarelto or Eliquis IS CONTRAINDICATED.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

PROLIA

Products Affected:

- Prolia SOLUTION 60 MG/ML
Subcutaneous

Details

Criteria
Claim will pay automatically for Prolia if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary bisphosphonates in the past 180 days. Otherwise, Prolia requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary bisphosphonates , OR (2) history of adverse event with any 2 generic formulary bisphosphonates, OR (3) any 2 generic formulary bisphosphonates are contraindicated. For osteoporosis prophylaxis in men at high risk for bone fractures after receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women at high risk for bone fractures after receiving adjuvant aromatase inhibitor therapy for breast cancer, Prolia will be approved.

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

RELPAK

Products Affected:

- Relpax TABLET 20 MG ORAL
- Relpax TABLET 40 MG ORAL

Details

Criteria	Claim will pay automatically for Relpax if enrollee has a paid claim for at least a 1 days supply of any formulary triptan (selective serotonin receptor agonist) in the past 365 days. Otherwise, Relpax requires a step therapy exception request indicating: (1) history of inadequate treatment response with any formulary triptan (selective serotonin receptor agonist), OR (2) history of adverse event with any formulary triptan (selective serotonin receptor agonist), OR (3) any formulary triptan (selective serotonin receptor agonist) is contraindicated.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

RHEUMATOID ARTHRITIS

Products Affected:

- Actemra SOLUTION 200 MG/10ML Intravenous
- Actemra SOLUTION 400 MG/20ML Intravenous
- Actemra SOLUTION 80 MG/4ML Intravenous
- Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous
- Cimzia KIT 2 X 200 MG Subcutaneous
- Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous
- Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous
- Orenzia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous
- Orenzia Solution Prefilled Syringe 125 MG/ML Subcutaneous
- Orenzia SOLUTION RECONSTITUTED 250 MG Intravenous
- Simponi Aria SOLUTION 50 MG/4ML Intravenous
- Simponi Solution Prefilled Syringe 100 MG/ML Subcutaneous
- Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous
- Stelara SOLUTION 130 MG/26ML Intravenous
- Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous
- Xeljanz TABLET 5 MG ORAL

Details

Criteria	
	CLAIM WILL PAY AUTOMATICALLY FOR THE REQUESTED DRUG (ACTEMRA, XELJANZ, STELARA, CIMZIA, SIMPONI, SIMPONI ARIA, ORENCIA OR KINERET) IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF HUMIRA AND ENBREL IN THE PAST 120 DAYS. OTHERWISE, THE REQUESTED DRUG REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH HUMIRA AND ENBREL, OR (2) HISTORY OF ADVERSE EVENT WITH HUMIRA AND ENBREL, OR (3) HUMIRA AND ENBREL ARE CONTRAINDICATED. FOR DIAGNOSIS OF CROHN'S DISEASE, CIMZIA WILL BE APPROVED AFTER TRIAL OF HUMIRA. FOR ULCERATIVE COLITIS, SIMPONI WILL BE APPROVED AFTER TRIAL OF HUMIRA. FOR CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES KINERET WILL BE APPROVED WITHOUT TRIAL OF HUMIRA AND/OR ENBREL.

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

TRINTELLIX

Products Affected:

- Trintellix TABLET 10 MG ORAL
- Trintellix TABLET 20 MG ORAL
- Trintellix TABLET 5 MG ORAL

Details

Criteria	Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, trintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressants, OR (3) any 2 generic formulary antidepressants are contraindicated.
-----------------	---

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

UCERIS

Products Affected:

- Uceris FOAM 2 MG/ACT Rectal
- Uceris Tablet Extended Release 24 Hour 9 MG Oral

Details

Criteria
Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 1 days supply of any formulary corticosteroid used to treat ulcerative colitis in the past 365 days. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated.

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

ULORIC

Products Affected:

- Uloric TABLET 40 MG ORAL
- Uloric TABLET 80 MG ORAL

Details

Criteria	Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past 365 days. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP) 2017 Step Therapy Criteria

VEMLIDY

Products Affected:

- Vemlidy TABLET 25 MG ORAL

Details

Criteria	Claim will pay automatically for Vemlidy if enrollee has a paid claim for at least a 1 days supply of lamivudine in the past 365 days. Otherwise, Vemlidy requires a step therapy exception request indicating: (1) history of inadequate treatment response with lamivudine, OR (2) history of adverse event with lamivudine, OR (3) lamivudine is contraindicated.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

VRAYLAR

Products Affected:

- Vraylar CAPSULE 1.5 MG Oral
- Vraylar CAPSULE 3 MG Oral
- Vraylar CAPSULE 4.5 MG ORAL
- Vraylar CAPSULE 6 MG ORAL
- Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral

Details

Criteria
Claim will pay automatically for VRAYLAR if enrollee has a paid claim for at least a 1 days supply of ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE or LATUDA in the past 365 days. Otherwise, Vraylar requires a step therapy exception request indicating any ONE of criteria 1, 2, 3, or 4: (1) history of inadequate treatment response with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE, or LATUDA or (2) history of adverse event with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE, or LATUDA or (3) ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, RISPERIDONE, QUETIAPINE XR, ZIPRASIDONE or LATUDA are contraindicated or (4) For diagnosis of MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER, THE COVERAGE DETERMINATION WILL BE APPROVED WITHOUT REQUIREMENT OF TRIAL AND FAILURE OR CONTRAINDICATION TO LATUDA.

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

XTANDI

Products Affected:

- Xtandi CAPSULE 40 MG ORAL

Details

Criteria	CLAIM WILL PAY AUTOMATICALLY FOR XTANDI IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF ZYTIGA IN THE PAST 365 DAYS. OTHERWISE, XTANDI REQUIRES A STEP THERAPY EXCEPTION REQUEST INDICATING: (1) HISTORY OF INADEQUATE TREATMENT RESPONSE WITH ZYTIGA, OR (2) HISTORY OF ADVERSE EVENT WITH ZYTIGA, OR (3) ZYTIGA IS CONTRAINDICATED.
-----------------	--

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

Alphabetical Listing

A

Actemra SOLUTION 200 MG/10ML Intravenous.....	11
Actemra SOLUTION 400 MG/20ML Intravenous.....	11
Actemra SOLUTION 80 MG/4ML Intravenous.....	11
Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous.....	11
Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular	1
Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular	1
Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular	1
Aubagio TABLET 14 MG ORAL	2
Aubagio TABLET 7 MG ORAL	2

B

Bystolic TABLET 10 MG ORAL.....	4
Bystolic TABLET 2.5 MG ORAL.....	4
Bystolic TABLET 20 MG ORAL.....	4
Bystolic TABLET 5 MG ORAL.....	4

C

Cimzia KIT 2 X 200 MG Subcutaneous... 11	
Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous	11

D

Difacid TABLET 200 MG ORAL.....	5
---------------------------------	---

F

FentaNYL Patch 72 Hour 100 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 25 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 37.5 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 50 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 62.5 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 75 MCG/HR Transdermal	6
FentaNYL Patch 72 Hour 87.5 MCG/HR Transdermal	6

K

Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous.....	11
---	----

M

Myrbetriq Tablet Extended Release 24 Hour 25 MG Oral	7
Myrbetriq Tablet Extended Release 24 Hour 50 MG Oral	7

O

Orencia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous.....	11
Orencia Solution Prefilled Syringe 125 MG/ML Subcutaneous.....	11
Orencia SOLUTION RECONSTITUTED 250 MG Intravenous	11

P

Pradaxa CAPSULE 110 MG ORAL.....	8
Pradaxa CAPSULE 150 MG ORAL.....	8
Prolia SOLUTION 60 MG/ML Subcutaneous	9

R

Rapaflo CAPSULE 4 MG ORAL.....	3
Rapaflo CAPSULE 8 MG ORAL.....	3
Relpax TABLET 20 MG ORAL.....	10
Relpax TABLET 40 MG ORAL.....	10

S

Simponi Aria SOLUTION 50 MG/4ML Intravenous.....	11
Simponi Solution Prefilled Syringe 100 MG/ML Subcutaneous.....	11
Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous.....	11
Stelara SOLUTION 130 MG/26ML Intravenous.....	11
Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous.....	11

T

Trintellix TABLET 10 MG ORAL.....	12
Trintellix TABLET 20 MG ORAL.....	12
Trintellix TABLET 5 MG ORAL.....	12

U

Uceris FOAM 2 MG/ACT Rectal.....	13
----------------------------------	----

Formulary ID: 17357 Version 16

Last Updated 05/24/2017

Effective date: 06/01/2017

HEALTH CHOICE GENERATIONS (PDP)

2017 Step Therapy Criteria

Uceris Tablet Extended Release 24 Hour 9 MG Oral	13
Uloric TABLET 40 MG ORAL.....	14
Uloric TABLET 80 MG ORAL.....	14
V	
Vemlidy TABLET 25 MG ORAL.....	15
VESIcare TABLET 10 MG ORAL	7
VESIcare TABLET 5 MG ORAL	7
Vraylar CAPSULE 1.5 MG Oral.....	16

Vraylar CAPSULE 3 MG Oral.....	16
Vraylar CAPSULE 4.5 MG ORAL	16
Vraylar CAPSULE 6 MG ORAL	16
Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral	16
X	
Xeljanz TABLET 5 MG ORAL	11
Xtandi CAPSULE 40 MG ORAL.....	17